NAS:AZRX (USA) Also Trade In: Germany
AzurRx BioPharma Inc $ 0.82 -0.01 (-1.26%)
Warning! GuruFocus has detected 2 Severe warning signs with AZRX. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for AzurRx BioPharma Inc () from 2016 to Sep 19 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. AzurRx BioPharma stock (AZRX) PE ratio as of Sep 19 2020 is 0. More Details
AzurRx BioPharma PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
AzurRx BioPharma PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare OTCPK:IGXT NAS:OCGN OTCPK:BSTG NAS:AIKI AMEX:NBY OTCPK:BIVI NAS:CBLI OTCPK:CTDH NAS:EYEG NAS:SLS OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 760 Parkside Avenue, Suite 304, Downstate Biotechnology Incubator, Brooklyn, NY, USA, 11226
AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).